

Q² acid sequence of a polypeptide defined in claim 1 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acid not naturally contiguous to the first portion in DP-1.

Q³ 10. (Amended) A pharmaceutical composition comprising a polypeptide according to ~~claim 1~~ together with a pharmaceutically acceptable diluent or carrier.

Q⁴ 12. (Amended) A polypeptide according to claim 1 for use in a method of treatment of the human or animal body.

13. (Amended) A method of inducing apoptosis in a cell which comprises introducing into said cell an effective amount of a polypeptide according to ~~claim 1~~.

Q⁵ 16. (Amended) A product comprising a polypeptide as defined in claim 1 and a cytostatic or cytotoxic agent as a combined preparation for separate or sequential use in a method of treatment of the human or animal body.

17. (Amended) A surgical stent which comprises a polypeptide as defined in claim 1 in a pharmaceutically acceptable carrier.

18. (Amended) An expression vector comprising a promoter operably linked to a sequence encoding a polypeptide as defined in claim 1.

Please add the following new claim.

Q⁶ -- 20. A composition according to claim 10 for use in a method of treating a human or animal body. --